- ONCT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing
Oncternal Therapeutics (ONCT) 8-KFinancial statements and exhibits
Filed: 20 Apr 04, 12:00am
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report:April 19, 2004
(Date of earliest event reported)
GTx, Inc.
Delaware | 005-79588 | 62-1715807 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
3 N. Dunlap Street
3rd Floor, Van Vleet Building
Memphis, Tennessee 38163
(901) 523-9700
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit No. | Description | |
99.1 | Press release dated April 19, 2004. |
ITEM 12. Results of Operations and Financial Condition
On April 19, 2004, GTx issued an earnings release for the first quarter ending March 31, 2004, a copy of which is furnished as Exhibit 99.1 to this Current Report.
This release is furnished by GTx pursuant to Item 12 of Form 8-K and is not to be considered “filed” under the Exchange Act, and shall not be incorporated by reference into any previous or future filing by the Registrant under the Securities Act or the Exchange Act.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GTx, INC. | ||||
Date: April 20, 2004 | By: | /s/ Mark E. Mosteller | ||
Name: | Mark E. Mosteller | |||
Title: | Chief Financial Officer (principal accounting and financial officer) |